Press "Enter" to skip to content

U.S. FDA gives early approval to Sarepta’s newest DMD treatment

The FDA in August had declined to approve the company’s marketing application for the drug, citing safety concerns including the risk of infection and kidney toxicity.

Original source:

Also Read:   Johnson & Johnson announces a Lead Vaccine Candidate for COVID-19